Clinical Trial

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-15; most recent amendment 2026-04-07.
Trial Details
NCT Number NCT06986434
Lead Sponsor Affiliated Hospital to Academy of Military Medical Sciences
Conditions Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation
Enrollment 20 participants
Start Date 2026-04-02
Primary Completion 2027-05-22 (estimated)
Study Completion 2028-08-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-08